Earnings ·
Aurinia Pharmaceuticals reported financial results for the three and six months ended June 30, 2026
AUPHAurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals reported financial results for the three and six months ended June 30, 2026. Total revenue increased 19% to $83.2 million in Q2 and 21% to $160.9 million year-to-date compared to prior-year periods. Net income rose 74% to $37.4 million in Q2 and 60% to $71.8 million for the first half of 2026. Diluted earnings per share reached $0.28 for the quarter and $0.53 year-to-date. The company reiterated its full-year 2026 total revenue guidance of $315 million to $325 million. Aurinia operates in the biopharmaceutical industry, developing therapies for autoimmune diseases.